Small Molecule Lonidamine derivatives that inhibit Hsp90 and, therefore, its protein clients including CFTR, B-Raf/ERK, ErbB2, and Cdk4

Track Code: 
09KU014M1
Summary: 

Lonidimine derivates can be used to inhibit Hsp90 and, therefore, treat, prevent and/or inhibit abnormal cell growth with a favorable toxicity profile.

Overview: 

A number of renal cystic diseases, including Von Hippel-Lindau (VHL), tuberous sclerosis (TSC), polycystic kidney disease (PKD), and acquired cystic disease (AcCD) are characterized by epithelial neoplastic growth, cyst formation and enlargement, and progression to adenoma and various malignancies, including oncocytoma, clear cell carcinoma, and papillary renal cell carcinoma. While the degree varies to which these disorders progress to metastasis, they all have in common 1) cyst formation, 2) neoplastic growth, and 3) tumor formation.

Our in-vivo and in-vitro studies to date have focused autosomal dominant polycystic kidney disease (ADPKD). ADPKD is characterized by abnormal proliferative growth of large epithelial-lined cysts from the nephrons and collecting ducts of affected kidneys. ADPKD is an inherited disease, affecting one in 500-1,000 individuals. Two genes give rise to ADPKD in humans - mutations in PKD1 cause ~85% of ADPKD cases and mutations in PKD2 cause ~15% of ADPKD cases. Cyst growth occurs slowly over decades. Eventually the cystic kidneys fail in about half of affected individuals by the time they reach their 50's. If cyst growth and enlargement could be slowed, renal failure could be put off by years or even decades, thus effectively delaying or preventing end-stage renal disease.

How it works: 

Using a metanephric mouse model with CFTR mutant mice (Pkd1 -/- : Cftr -/-), our data indicates that cyst formation is stimulated by activation of the CFTR chloride channel on the apical membrane of cyst-lining epithelial cells, thus allowing net chloride secretion and ultimately increased fluid transport into the cyst. cAMP activation of CFTR and B-Raf1 both stimulates cyst proliferation and inhibits the proliferation of normal cells.

Our studies are the first to test Lonidamine and its derivatives as a therapy for PKD, and these are the first studies to test an Hsp90 inhibitor on PKD.

Benefits: 

Inhibition of CFTR and B-Raf, thereby slowing cyst enlargement and preserving kidney function in a dose-dependent manner in patients with polycystic kidney disease (PKD). CFTR and B-Raf have been implicated in both cyst proliferation and fluid secretion in PKD.

Why it is better: 

There is currently no cure for PKD. Transplantation is an option generally only available to those in end stage renal disease (ESRD). Slowing cyst growth and proliferation could effectively delay or prevent ESRD.

Other Applications: 

Our Hsp90 inhibitors could be tested not just in PKD, but several other disease states that involve uncontrolled or abnormal cell proliferation.

Licensing Associate: 
Aswini Betha, PhD · abetha@ku.edu · 913-588-5713
Subcategory(s): 
Keyword(s): 
Inventor(s): 
Joseph Tash
Gunda Georg
Ramappa Chakrasali
Sudhakar Jakkaraj
James Calvet
Patent(s): 
US 8,362,031
Status: 
Patented